Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

NCT00193622 ↗

Phase 2 Completed 50 enrolled SCRI Development Innovations, LLC Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor.

Timeline

Start: 2004-04
Primary completion: 2005-09
Completion: 2009-01

Publications

Results Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007 May 1;25(13):1747-52. doi: 10.1200/JCO.2006.09.3047.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Erlotinib	Small molecule	150 mg	Oral

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Summary

Timeline

Publications

Drugs

Indications